Table 1. Patient characteristics.
| EOX (n=17) | OX (n=19) | X (n=19) | Total (n=55) | |
|---|---|---|---|---|
|
Sex | ||||
| Men | 13 (76%) | 13 (68%) | 15 (79%) | 41 (75%) |
| Women | 4 (24%) | 6 (32%) | 4 (21%) | 14 (25%) |
|
Age (years) | ||||
| Median | 74 | 77 | 75 | 75 |
| IQR | 70–77 | 70–79 | 70–78 | 70–78 |
| Range | 64–82 | 50–85 | 57–87 | 50–87 |
|
WHO performance status | ||||
| 0 | 0 (0%) | 4 (21%) | 2 (11%) | 6 (11%) |
| 1 | 11 (65%) | 10 (53%) | 10 (53%) | 31 (56%) |
| 2 | 6 (35%) | 5 (26%) | 7 (37%) | 18 (33%) |
|
Primary tumour site | ||||
| Oesophagus | 5 (29%) | 11 (58%) | 8 (42%) | 24 (44%) |
| Gastroesophageal junction | 2 (12%) | 1 (5%) | 4 (21%) | 9 (16%) |
| Gastric | 10 (59%) | 5 (26%) | 7 (37%) | 22 (40%) |
| Unknown | 0 (0%) | 1 (5%) | 0 (0%) | 1 (2%) |
|
Metastases | ||||
| Yes | 17 (100%) | 17 (89%) | 18 (95%) | 52 (95%) |
| No | 0 (0%) | 2 (11%) | 1 (5%) | 3 (5%) |
|
Histology | ||||
| Squamous cell carcinoma | 2 (12%) | 3 (16%) | 1 (5%) | 6 (11%) |
| Adenocarcinoma | 15 (88%) | 15 (79%) | 18 (95%) | 48 (87%) |
| Mixed squamous+adenocarcinoma | 0 (0%) | 1 (5%) | 0 (0%) | 1 (2%) |
Abbreviations: EOX=epirubicin, oxaliplatin and capecitabine; IQR=interquartile range; OX=oxaliplatin and capecitabine; WHO=World Health Organisation; X=capecitabine.